CIC
LLY icon

Carnegie Investment Counsel’s Eli Lilly LLY Stock Holding History

Carnegie Investment Counsel’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.8M Buy
11,755
+215
+2% +$218K 0.21% 122
2025
Q4 		$12.4M Sell
11,540
-894
-7% -$855K 0.23% 117
2025
Q3 		$9.49M Sell
12,434
-138
-1% -$103K 0.18% 140
2025
Q2 		$9.8M Buy
12,572
+3,193
+34% +$2.48M 0.2% 135
2025
Q1 		$6.92M Buy
9,379
+917
+11% +$763K 0.16% 141
2024
Q4 		$6.53M Buy
8,462
+1,194
+16% +$989K 0.19% 133
2024
Q3 		$6.44M Buy
7,268
+456
+7% +$410K 0.19% 128
2024
Q2 		$6.17M Buy
6,812
+105
+2% +$84K 0.19% 116
2024
Q1 		$5.22M Buy
6,707
+17
+0.3% +$12.1K 0.16% 136
2023
Q4 		$3.9M Buy
6,690
+15
+0.2% +$8.76K 0.13% 156
2023
Q3 		$3.59M Sell
6,675
-309
-4% -$159K 0.14% 154
2023
Q2 		$3.28M Buy
6,984
+1,197
+21% +$502K 0.12% 162
2023
Q1 		$1.99M Buy
5,787
+3
+0.1% +$1.01K 0.08% 205
2022
Q4 		$2.12M Buy
5,784
+205
+4% +$72.7K 0.09% 198
2022
Q3 		$1.8M Sell
5,579
-1,782
-24% -$565K 0.09% 200
2022
Q2 		$2.39M Sell
7,361
-359
-5% -$108K 0.11% 178
2022
Q1 		$2.21M Sell
7,720
-388
-5% -$99.9K 0.08% 194
2021
Q4 		$2.24M Buy
8,108
+1,920
+31% +$487K 0.07% 194
2021
Q3 		$1.43M Sell
6,188
-68
-1% -$16.8K 0.05% 220
2021
Q2 		$1.44M Buy
6,256
+255
+4% +$51.2K 0.05% 222
2021
Q1 		$1.12M Buy
6,001
+507
+9% +$99.2K 0.05% 238
2020
Q4 		$928K Buy
5,494
+4
+0.1% +$597 0.04% 238
2020
Q3 		$813K Sell
5,490
-6
-0.1% -$929 0.04% 231
2020
Q2 		$902K Sell
5,496
-759
-12% -$117K 0.05% 222
2020
Q1 		$868K Sell
6,255
-131
-2% -$18K 0.06% 208
2019
Q4 		$839K Buy
6,386
+1,158
+22% +$134K 0.05% 239
2019
Q3 		$585K Buy
5,228
+97
+2% +$10.8K 0.04% 271
2019
Q2 		$568K Sell
5,131
-508
-9% -$59.8K 0.04% 288
2019
Q1 		$732K Buy
5,639
+403
+8% +$49K 0.05% 247
2018
Q4 		$606K Sell
5,236
-2,731
-34% -$305K 0.06% 236
2018
Q3 		$907K Buy
7,967
+2,842
+55% +$284K 0.07% 200
2018
Q2 		$525K Buy
5,125
+4
+0.1% +$329 0.04% 263
2018
Q1 		$422K Sell
5,121
-275
-5% -$22.1K 0.04% 266
2017
Q4 		$414K Buy
5,396
+459
+9% +$39.1K 0.04% 291
2017
Q3 		$430K Buy
4,937
+66
+1% +$5.41K 0.05% 254
2017
Q2 		$399K Buy
4,871
+4
+0.1% +$326 0.05% 259
2017
Q1 		$394K Buy
4,867
+4
+0.1% +$320 0.05% 252
2016
Q4 		$368K Sell
4,863
-96
-2% -$7.15K 0.05% 246
2016
Q3 		$389K Sell
4,959
-196
-4% -$15.7K 0.06% 239
2016
Q2 		$430K Buy
5,155
+604
+13% +$45.5K 0.06% 237
2016
Q1 		$328K Buy
4,551
+254
+6% +$19.2K 0.05% 244
2015
Q4 		$340K Sell
4,297
-346
-7% -$28.7K 0.06% 233
2015
Q3 		$376K Buy
4,643
+154
+3% +$13K 0.06% 223
2015
Q2 		$375K Sell
4,489
-197
-4% -$15K 0.07% 219
2015
Q1 		$344K Buy
4,686
+211
+5% +$15K 0.06% 228
2014
Q4 		$317K Buy
4,475
+24
+0.5% +$1.62K 0.06% 220
2014
Q3 		$289K Buy
+4,451
New +$282K 0.06% 238

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Carnegie Investment Counsel's LLY Position: Q1 2026 in Review

Carnegie Investment Counsel increased its Eli Lilly (LLY) stake by 1.9% in Q1 2026, buying an estimated $218K and bringing the position to 11,755 shares worth $10.8M. The position accounts for 0.21% of the portfolio, ranked #122.

Carnegie Investment Counsel first reported a position in LLY in Q3 2014 and has held it in 47 quarters since. The position peaked at $12.4M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Carnegie Investment Counsel held 11,755 shares of Eli Lilly worth $10.8M as of Q1 2026.
  • Carnegie Investment Counsel bought 215 Eli Lilly shares in Q1 2026, an estimated $218K.
  • Eli Lilly made up 0.21% of Carnegie Investment Counsel's portfolio in Q1 2026, its #122 holding.
  • Carnegie Investment Counsel first reported a position in Eli Lilly in Q3 2014 and has held it in 47 quarters since.
  • Carnegie Investment Counsel's Eli Lilly position peaked at $12.4M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Carnegie Investment Counsel's 13F filing for Q1 2026, filed 1 May 2026.